{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:38:43Z","timestamp":1783996723167,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Dalbavancin is a new antibiotic that is effective against Gram-positive microorganisms, including methicillin-resistant Staphylococci, and offers the possibility of administering intravenous therapy once weekly in an ambulatory setting. We conducted a multicenter observational case-control study, comparing all patients who received dalbavancin (cases) with hospitalized patients who were treated instead with daptomycin, linezolid or vancomycin (controls), based on clinical diagnosis, main microorganism involved, and age. The primary outcome was the length of hospital stay after starting the study antimicrobial. Secondary outcomes were 7-day and 30-day efficacy, 30-day mortality, 90-day recurrence, 90-day and 6-month hospitalization, presence of adverse events and healthcare-associated infections; 161 patients (44 cases and 117 controls) were included. Bivariate analysis showed that dalbavancin reduced the total length of hospital stay (p &lt; 0.001), with fewer 90-day recurrences (p = 0.005), 6-month hospitalizations related to the same infection (p = 0.004) and non-related hospitalizations (p = 0.035). Multivariate analyses showed that length of hospital stay was significantly shorter in patients treated with dalbavancin (\u221212.05 days 95% CI [\u221217.00, \u22127.11], p &lt; 0.001), and 30-day efficacy was higher in the dalbavancin group (OR 2.62 95% CI [1.07, 6.37], p = 0.034). Although sample size of the study may be a limitation, we can conclude that Dalbavancin is a useful antimicrobial drug against Gram-positive infections, including multidrug-resistant pathogens, and allows for a remarkable reduction in length of hospital stay with greater 30-day efficacy.<\/jats:p>","DOI":"10.3390\/antibiotics10111296","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:06:16Z","timestamp":1635113176000},"page":"1296","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality"],"prefix":"10.3390","volume":"10","author":[{"given":"Mar","family":"de Pablo-Mir\u00f3","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"},{"name":"Faculty of Health and Life Sciencies, Universitat Pompeu Fabra, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Pujol-Ruiz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"},{"name":"Faculty of Health and Life Sciencies, Universitat Pompeu Fabra, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Iftimie","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"Arenas-Miras","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-4412","authenticated-orcid":false,"given":"Inmaculada","family":"L\u00f3pez-Montesinos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Duran-Jord\u00e0","sequence":"additional","affiliation":[{"name":"Statistics Service, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Angl\u00e8s","sequence":"additional","affiliation":[{"name":"Documentation Service, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-1836","authenticated-orcid":false,"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Faculty of Health and Life Sciencies, Universitat Pompeu Fabra, 08003 Barcelona, Spain"},{"name":"Pharmacy Service, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"REIPI (Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00edas Infecciosas)\u2014ISCII (Instituto de Salud Carlos III) Spanish Network for Research in Infectious Diseases, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-5459","authenticated-orcid":false,"given":"Juan P.","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), 08003 Barcelona, Spain"},{"name":"Faculty of Health and Life Sciencies, Universitat Pompeu Fabra, 08003 Barcelona, Spain"},{"name":"REIPI (Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00edas Infecciosas)\u2014ISCII (Instituto de Salud Carlos III) Spanish Network for Research in Infectious Diseases, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,24]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020, May 05). Global Action Plan on Antimicrobial Resistance. Available online: https:\/\/www.who.int\/antimicrobial-resistance\/global-action-plan\/en\/."},{"key":"ref_2","unstructured":"O\u2019Neill, J. (2021, May 19). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Available online: https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vazquez-Guillamet, C., and Kollef, M.H. (2014). Treatment of gram\u2014positive infections in critically ill patients. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-92"},{"key":"ref_4","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2020, October 12). Antimicrobial Resistance in the EU\/EEA (EARS-Net): Annual Epidemiological Report for 2019, Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/surveillance-antimicrobial-resistance-Europe-2019.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","unstructured":"European Medicines Agency (EMA) (2021, October 07). Xydalba EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xydalba-epar-product-information_en.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","article-title":"Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: Systematic review, network meta-analysis and cost analysis","volume":"24","author":"Agarwal","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: A real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/phar.2389","article-title":"Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review","volume":"40","author":"Krsak","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40121-021-00402-0","article-title":"Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials","volume":"10","author":"Gonzalez","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","first-page":"Doc03","article-title":"Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment\u2014A health economic analysis using German DRG data","volume":"7","author":"Wilke","year":"2019","journal-title":"GMS Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-Acting Lipoglycopeptides: \u201cLineless Antibiotics\u201d for Serious Infections in Persons Who Use Drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Vinuesa","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guest, J.F., Esteban, J., Manganelli, A.G., Novelli, A., Rizzardini, G., and Serra-Burriel, M. (2017). Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187792"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5114\/ait.2019.86275","article-title":"Validation of APACHE II and SAPS II scales at the intensive care unit along with assessment of SOFA scale at the admission as an isolated risk of death predictor","volume":"51","author":"Borowska","year":"2019","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"ref_28","unstructured":"World Health Organization (2020, May 05). The Burden of Health Care-Associated Infection Worldwide. Available online: https:\/\/www.who.int\/gpsc\/country_work\/burden_hcai\/en\/."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1296\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:22Z","timestamp":1760167342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,24]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["antibiotics10111296"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10111296","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,24]]}}}